Latest:
Hematologic Malignancies Talk: Exciting Updates from ASH 2020 Virtual Meeting
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Eric K. Singhi, MD
Eric K. Singhi, MD, is an assistant professor in the Department of General Oncology in the Division of Cancer Medicine and in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston.
Latest:
Eye-Catching Data From the 2025 World Conference on Lung Cancer
Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss key data from the 2025 World Conference on Lung Cancer.
John Chung-Kai Chan, MD
Latest:
Future of Gynecologic Oncology: Integrating Antibody-Drug Conjugates and Novel Combinations Into the IO Sequencing Paradigm for Advanced EC
Panelists discuss how future therapies, such as antibody-drug conjugates (ADCs) and novel combination therapies, could enhance immuno-oncology (IO) sequencing by offering more targeted options for patients who have progressed on initial IO therapies, while addressing resistance mechanisms and improving overall treatment outcomes.
Christina Brennan, MD, MBA, FACRP
Christina Brennan, MD, MBA, FACRP, is senior vice president of clinical research at The Feinstein Institutes for Medical Research at Northwell Health.
Latest:
A Close Look at Clinical Trials in Oncology and Beyond: Looking Toward the Future
In this last episode, experts underscore the importance of incorporating the patient voice into clinical trial processes.
Pannaga G. Malalur, MBBS
Latest:
Dr Malalur on Addressing Unmet Needs in Pancreatic Cancer
Pannaga G. Malalur, MBBS, discusses several unmet needs within pancreatic cancer, including the implementation of updated germline genetic testing guidelines, increased screening of high-risk patients, and improved sequencing of available therapeutics.
Nisha Joseph, MD
Nisha Joseph, MD, is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine
Latest:
FDA Approval Insights: Linvoseltamab in Relapsed/Refractory Multiple Myeloma: With Nisha Joseph, MD; and Hans Lee, MD
Drs Lee and Joseph discuss the significance of the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.
Priscilla Merriam, MD
Latest:
Supporting Community Practice Through Collaboration
Panelists discuss how communication between community oncologists and academic centers is essential for advancing gastrointestinal stromal tumor (GIST) treatment through clinical trial participation, molecular analysis, and the promising future of personalized therapy based on individual tumor mutation profiles.
Regina Barragan-Carrillo, MD
Regina Barragan-Carrillo, MD, is a postdoctoral research fellow at City of Hope Comprehensive Cancer Center.
Latest:
Dr Barragan-Carrillo on Global Disparities in Clinical Trial Availability in RCC
Regina Barragan-Carrillo, MD, discusses findings from an analysis of global RCC clinical trial availability in high- vs low-to-middle–income countries.
Rachna T. Shroff, MD, MS, FASCO
Rachna Shroff, MD, MS, FASCO, is interim clinical affairs director, associate director of Clinical Investigations, and co-lead of Gastrointestinal Clinical Research Team at The University of Arizona Cancer Center. She is also a professor in the Department of Medicine, chief of the Division of Hematology/Oncology, medical director of the Oncology Service Line, and associate dean of Clinical and Translational Research at The University of Arizona College of Medicine.
Latest:
ASCO 2025 Spotlight: RASolute 302 Trial Design and Daraxonrasib’s Clinical Potential
A new phase 3 trial evaluating an oral RAS-ON inhibitor in patients with advanced pancreatic cancer after frontline chemotherapy marks a major step toward potentially redefining second-line treatment, offering a targeted, patient-friendly alternative to standard chemotherapy with the hope of improving both outcomes and quality of life.